Medical tech firm Nyxoah's EPS forecast for FY2024 lowered by analysts, target prices adjusted.

Medical tech firm Nyxoah's (NYXH) EPS forecast has been lowered to ($1.98) per share for FY2024 by Cantor Fitzgerald, while maintaining an "Overweight" rating and a $16.00 price objective. Oppenheimer cut its price target from $15 to $13, keeping an "outperform" rating. Other analysts have also issued reports on the stock, with Cantor Fitzgerald reducing its target price from $18 to $17 and issuing an "overweight" rating, and Stifel Nicolaus lowering its target price from $27 to $19 while maintaining a buy rating. HC Wainwright reaffirmed a buy rating and set a $18 price objective. Nyxoah focuses on sleep disordered breathing conditions, with its lead product being the Genio system, a hypoglossal neurostimulation therapy for moderate to severe obstructive sleep apnea.